Articles & Whitepapers
The opioid crisis in the United States is a devastating public health issue, with over 70,000 overdose deaths annually, largely driven by the highly potent synthetic opioid fentanyl. The urgency to address this crisis has spurred the development of innovative therapies to prevent and reverse fentanyl overdoses. In this blog, we will explore the groundbreaking preclinical work on CSX-1004, a fully ...
Comprehensive Guide to Building and Maintaining First Aid Kits for Home and Emergency Preparedness Introduction Life is full of challenges, from unexpected injuries to sudden emergencies. Some we ...
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol ...
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
Equipment & Solutions
We were the first in the world to develop ‘hot sensation plasters’ and ‘analgesic and anti-inflammatory plasters’.